Gene · 64783
Papers2,224
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
181 to 200 of 2,224
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| m6A methylation modification and immune cell infiltration: implications for targeting the catalytic subunit m6A-METTL complex in gastrointestinal cancer immunotherapy. | Front Immunol | 2023 | 38187373 | PubTator, text mining | PubMed |
| Investigating the prognostic value of m6A methylation-related genes in renal cell carcinoma patients. | Eur Rev Med Pharmacol Sci | 2023 | 38164857 | PubTator, text mining | PubMed |
| CD24 May Serve as an Immunotherapy Target in Triple-Negative Breast Cancer by Regulating the Expression of PD-L1. | Breast Cancer (Dove Med Press) | 2023 | 38164371 | PubTator, text mining | PubMed |
| Potential role of N6-methyladenosine modification in the development of Parkinson's disease. | Front Cell Dev Biol | 2023 | 38155838 | PubTator, text mining | PubMed |
| Epigenetic targeting of autophagy for cancer: DNA and RNA methylation. | Front Oncol | 2023 | 38148841 | PubTator, text mining | PubMed |
| Intron Editing Reveals SNORD-Dependent Maturation of the Small Nucleolar RNA Host Gene GAS5 in Human Cells. | Int J Mol Sci | 2023 | 38139448 | PubTator, text mining | PubMed |
| The Construction and Validation of a Novel Ferroptosis-Related Gene Signature in Parkinson's Disease. | Int J Mol Sci | 2023 | 38139032 | PubTator, text mining | PubMed |
| Molecular Characterization and Establishment of a Prognostic Model Based on Primary Immunodeficiency Features in Association with RNA Modifications in Triple-Negative Breast Cancer. | Genes (Basel) | 2023 | 38136994 | PubTator, text mining | PubMed |
| New understandings of the genetic regulatory relationship between non-coding RNAs and m6A modification. | Front Genet | 2023 | 38125749 | PubTator, text mining | PubMed |
| The role of RNA modification in urological cancers: mechanisms and clinical potential. | Discov Oncol | 2023 | 38117350 | PubTator, text mining | PubMed |
| Novel insights into the regulatory role of N6-methyladenosine methylation modified autophagy in sepsis. | Aging (Albany NY) | 2023 | 38112620 | PubTator, text mining | PubMed |
| Non-coding RNA methylation modifications in hepatocellular carcinoma: interactions and potential implications. | Cell Commun Signal | 2023 | 38111040 | PubTator, text mining | PubMed |
| Identification of TMEM178 as a Potential Prognostic Biomarker and Therapeutic Target for Breast Cancer. | Iran J Public Health | 2023 | 38106832 | PubTator, text mining | PubMed |
| The role of m6A epigenetic modifications in tumor coding and non-coding RNA processing. | Cell Commun Signal | 2023 | 38102645 | PubTator, text mining | PubMed |
| Role of YES1 signaling in tumor therapy resistance. | Cancer Innov | 2023 | 38089407 | PubTator, text mining | PubMed |
| Role of N6-methyladenosine methylation in glioma: recent insights and future directions. | Cell Mol Biol Lett | 2023 | 38072944 | PubTator, text mining | PubMed |
| The epitranscriptome of high-grade gliomas: a promising therapeutic target with implications from the tumor microenvironment to endogenous retroviruses. | J Transl Med | 2023 | 38071304 | PubTator, text mining | PubMed |
| m6A modification patterns are associated with copy number burden and tumor immune landscape in thyroid cancer. | BMC Endocr Disord | 2023 | 38057752 | PubTator, text mining | PubMed |
| METTL16 in human diseases: What should we do next? | Open Med (Wars) | 2023 | 38045858 | PubTator, text mining | PubMed |
| Identification and validation of N6-methyladenosine (m6A)-related lncRNAs signature for predicting the prognosis of laryngeal carcinoma, especially for smoking patients. | Front Genet | 2023 | 38028627 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/64783/papers?page=10